Deutsche Bank Downgrades DiaSorin to 'Sell' on 2026 Risk

By EC Assets · Published 17 June 2026

Deutsche Bank has downgraded DiaSorin to "Sell" from "Hold." The firm also trimmed its price target for the Italian diagnostics company by 6.5%. This downgrade is attributed to risks in 2026. DiaSorin is an Italian multinational active in diagnostics. The company is included in the FTSE MIB. Its business competencies include the development of medical technology. Jan Koch, an analyst at Deutsche Bank, issued the downgrade. Following the announcement, DiaSorin saw its stock decline. The company lost over 2% and was the worst blue chip on the FtseMib. The shares are traded under the ISIN IT0003492391. This article is intended for informational purposes only. It does not constitute investment advice.